See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Surveys, Polls and Research
Reportlinker Adds Epigenetics Therapeutics to 2017 - High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma
NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0286300/Epigenetics-Therapeutics-to-2017-–-High-Market-Potential-for-Epigenetics-Drugs-in-Acute-Myeloid-Leukemia-Multiple-Myeloma-and-Cutaneous-T-Cell-Lymphoma.html
Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma
Summary
GBI Research's report, "Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma", provides in-depth analysis of trends, issues and challenges in this industry. The report analyzes the technology that shape the industry dynamics for the key geographies: the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Further, the report provides competitive benchmarking for the leading companies and analyzes the licensing agreements that shape the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
Scope
The Scope of this report includes:
- Annualized market data from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading technology in this space
- Market characterization
- Key drivers and barriers that have a significant impact on the market.
- Competitive benchmarking of leading companies.
Reasons to buy
The report will enhance your decision making capability. It will allow you to
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
| 1 Table of Contents 3 1.1 List of Tables 5 1.2 List of Figures 6 2 Introduction 7 2.1 GBI Research Report Guidance 7 3 Market Characterization: Global Epigenetics Market 8 3.1 Disease Overview 8 3.1.1 Myelodysplastic Syndrome 8 3.1.2 Cutaneous T-cell Lymphoma 8 3.2 Epigenetic Drugs 9 3.3 The US 11 3.4 Top Five European Markets 12 3.5 Japan 14 4 In-Depth Analysis 16 4.1 Introduction 16 4.2 Vidaza (Azacitidine) 16 4.2.1 Indication 16 4.2.2 Mechanism of Action 16 4.2.3 Revenue Forecast 16 4.2.4 Key Takeaway 23 4.2.5 Market Potential 23 4.2.6 Pipeline Analysis 29 4.2.7 Drug Profile 32 4.3 Dacogen (Decitabine) 33 4.3.1 Indication 33 4.3.2 Mechanism of action 33 4.3.3 Revenue Forecast 34 4.3.4 Key Takeaway 39 4.3.5 Market Potential 39 4.3.6 Pipeline Analysis 45 4.3.7 Drug Profile 48 4.4 Zolinza (Vorinostat) 49 4.4.1 Indication 49 4.4.2 Mechanism of Action 49 4.4.3 Revenue Forecast 49 4.4.4 Disease Overview 55 4.4.5 Market Potential 55 4.4.6 Pipeline Analysis 61 4.4.7 Drug Profile 63 4.5 Istodax (Romidepsin) 64 4.5.1 Indication 64 4.5.2 Disease Overview 64 4.5.3 Mechanism of Action 65 4.5.4 Market Potential 65 4.5.5 Pipeline Analysis 71 4.5.6 Clinical Studies by Phases 71 4.5.7 Clinical Studies by Indication 72 4.5.8 Drug Profile 73 5 Competitive Landscape 75 5.1 Merck & Co. 75 5.1.1 Company Overview 75 5.1.2 Business Description 75 5.1.3 SWOT 77 5.2 Celgene Corporation 77 5.2.1 Company Overview 77 5.2.2 Business Description 78 5.2.3 SWOT 79 5.3 EISAI 80 5.3.1 Company Overview 80 5.3.2 Business Description 80 5.3.3 SWOT 82 6 Epigenetic Therapeutics: Appendix 83 6.1 Market Definitions 83 6.2 Abbreviations 83 6.3 Research Methodology 84 6.3.1 Coverage 85 6.3.2 Secondary Research 85 6.3.3 Primary Research 85 6.3.4 Forecasts 86 6.3.5 Expert Panel Validation 88 6.4 Contact Us 88 6.5 Disclaimer 88 6.6 Sources 88 1.1 List of Tables Table 1: List of Approved Epigenetic Drugs, 2010 8 Table 2: Epigenetic Therapeutics Market, Global, Revenue Forecast ($m) 2009–2017 9 Table 3: Epigenetic Therapeutics Market, by Geography, Revenue Forecast ($m) 2009–2017 10 Table 4: Epigenetic therapeutics Market, The US, Revenue Forecast ($m) 2009 - 2017 12 Table 5: Epigenetic Therapeutics Market, Europe, Revenue Forecast ($m), 2009- 2017 13 Table 6: Epigenetic Therapeutics Market, Japan, Revenue Forecast ($m), 2009–2017 15 Table 7: Vidaza – Snapshot, 2010 16 Table 8: Vidaza, Global, Revenue Forecast ($m) 2009–2017 17 Table 9: Vidaza, By Geography, Revenue Forecast ($m )2009 - 2017 18 Table 10: Vidaza, The US, Revenue Forecast ($m) 2009–2017 19 Table 11: Vidaza, Europe, Revenue Forecast ($m), 2009–2017 21 Table 12: Vidaza, Japan, Revenue Forecast ($m), 2009–2017 22 Table 13: Vidaza Market Potential, Global, Revenue Forecast ($m) 2012–2017 24 Table 14: Vidaza Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 25 Table 15: Vidaza Market Potential, The US, Revenue Forecast ($m), 2012–2017 26 Table 16: Vidaza Market Potential, Europe, Revenue Forecast ($m), 2012–2017 27 Table 17: Vidaza Market Potential, Japan, Revenue Forecast ($m), 2012–2017 28 Table 18: Efficacy of Vidaza in MDS Patients, 2010 32 Table 19: Dacogen – Snapshot, 2010 33 Table 20: Dacogen, Global, Revenue Forecast ($m), 2009–2017 34 Table 21: Dacogen, By Geography, Revenue Forecast ($m), 2009–2017 35 Table 22: Dacogen, The US, Revenue Forecast ($m), 2009–2017 36 Table 23: Dacogen, Europe, Revenue Forecast ($m), 2009– 2017 38 Table 24: Dacogen, Japan, Revenue Forecast ($m), 2009–2017 39 Table 25: Dacogen, Market Potential, Global, Revenue Forecast ($m), 2012–2017 40 Table 26: Dacogen Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 41 Table 27: Dacogen, Market Potential, The US, Revenue Forecast ($m), 2012–2017 42 Table 28: Dacogen Market Potential, Europe, Revenue Forecast ($m), 2012–2017 43 Table 29: Dacogen, Market Potential, Japan, Revenue Forecast ($m), 2012–2017 44 Table 30: Zolinza Snapshot, 2010 49 Table 31: Zolinza, Global, Revenue Forecast ($m), 2010–2017 50 Table 32: Zolinza, By Geography, Revenue Forecast ($m), 2010–2017 51 Table 33: Zolinza, The US, Revenue Forecast ($m), 2010–2017 52 Table 34: Zolinza, Europe, Revenue Forecast ($m), 2010–2017 53 Table 35: Zolinza, Japan, Revenue Forecast ($m), 2010–2017 54 Table 36: Zolinza Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 56 Table 37: Zolinza, Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 57 Table 38: Zolinza Market Potential, The US, Revenue Forecast ($m), 2012–2017 58 Table 39: Zolinza Market Potential, Europe, Revenue Forecast ($m), 2012–2017 59 Table 40: Zolinza Market Potential, Japan, Revenue Forecast ($m), 2012–2017 60 Table 41: Istodax Snapshot, 2010 64 Table 42: Istodax Market Potential, By Geography, Revenue Forecast ($m), 2010–2017 66 Table 43: Istodax Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 67 Table 44: Istodax Market Potential, The US, Revenue Forecast ($m), 2010–2017 68 Table 45: Istodax Market Potential, Europe, Revenue Forecast ($m), 2010–2017 69 Table 46: Istodax Market Potential, Japan, Revenue Forecast ($m), 2010–2017 70 1.2 List of Figures Figure 1: Epigenetic Therapeutics Market, Global, Revenue Forecast ($m) 2009–2017 9 Figure 2: Epigenetic therapeutics Market, by Geography, Revenue Forecast ($m) 2009–2017 10 Figure 3: Epigenetic Therapeutics Market, The US, Revenue Forecast ($m) 2009–2017 11 Figure 4: Epigenetic Therapeutics Market, Europe, Revenue Forecast ($m), 2009–2017 13 Figure 5: Epigenetic Therapeutics Market, Japan, Revenue Forecast ($m) 2009–2017 14 Figure 6: Vidaza, Global, Revenue Forecast ($m) 2009–2017 17 Figure 7: Vidaza, By Geography, Revenue Forecast ($m) 2009–2017 18 Figure 8: Vidaza, The US, Revenue Forecast ($m) 2009–2017 19 Figure 9: Vidaza, Europe, Revenue Forecast ($m) 2009–2017 20 Figure 10: Vidaza, Japan, Revenue Forecast ($m), 2009–2017 22 Figure 11: Vidaza Market Potential, Global, Revenue Forecast ($m), 2012–2017 24 Figure 12: Vidaza Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 25 Figure 13: Vidaza Market Potential, The US, Revenue Forecast ($m), 2012–2017 26 Figure 14: Vidaza Market Potential, Europe, Revenue Forecast ($m), 2012–2017 27 Figure 15: Vidaza Market Potential, Japan, Revenue Forecast ($m), 2012–2017 28 Figure 16: Vidaza (Azacitidine) – Drug Pipeline, by Phase, 2010 29 Figure 17: Vidaza (Azacitidine) – Drug Pipeline, by Indication, 2009 30 Figure 18: Vidaza (Azacitidine) – Drug Pipeline, by Phase and Indication, 2010 31 Figure 19: Dacogen , Global, Revenue Forecast ($m), 2009–2017 34 Figure 20: Dacogen, By Geography, Revenue Forecast ($m), 2009–2017 35 Figure 21: Dacogen, The US, Revenue Forecast ($m), 2009–2017 36 Figure 22: Dacogen, Europe, Revenue Forecast ($m), 2009–2017 37 Figure 23: Dacogen, Japan, Revenue Forecast ($m), 2009–2017 38 Figure 24: Dacogen, Market Potential, Global, Revenue Forecast ($m), 2012–2017 40 Figure 25: Dacogen Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 41 Figure 26: Dacogen Market Potential, The US, Revenue Forecast ($m), 2012–2017 42 Figure 27: Dacogen Market Potential, Europe, Revenue Forecast ($m), 2012–2017 43 Figure 28: Dacogen Market Potential, Japan, Revenue Forecast ($m), 2012–2017 44 Figure 29: Dacogen (Decitabine) – Drug Pipeline, by Phase, 2010 45 Figure 30: Dacogen (Decitabine) – Drug Pipeline, by Indication, 2010 46 Figure 31: Dacogen (Decitabine) – Drug Pipeline, by Phase and Indication, 2010 47 Figure 32: Zolinza, Global, Revenue Forecast ($m), 2010–2017 50 Figure 33: Zolinza, Global, Revenue Forecast ($m), 2010–2017 51 Figure 34: Zolinza, The US, Revenue Forecast ($m), 2010–2017 52 Figure 35: Zolinza, Europe, Revenue Forecast ($m), 2010–2017 53 Figure 36: Zolinza, Japan, Revenue Forecast ($m), 2010–2017 54 Figure 37: Zolinza Market Potential, Global, Revenue Forecast ($m), 2012–2017 56 Figure 38: Zolinza, Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 57 Figure 39: Zolinza Market Potential, The US, Revenue Forecast ($m), 2012–2017 58 Figure 40: Zolinza Market Potential, Europe, Revenue Forecast ($m), 2012–2017 59 Figure 41: Zolinza Market Potential, Japan, Revenue Forecast ($m), 2012–2017 60 Figure 42: Zolinza (vorinostat) – Drug Pipeline, by Phase, 2010 61 Figure 43: Zolinza (vorinostat) – Drug Pipeline, by Indication, 2009 62 Figure 44: Zolinza (vorinostat) – Drug Pipeline, by Phase and Indication, 2010 63 Figure 45: Istodax Market Potential, Global, Revenue Forecast ($m), 2010–2017 66 Figure 46: Istodax Market Potential, By Geography, Revenue Forecast ($m), 2012–2017 67 Figure 47: Istodax Market Potential, The US, Revenue Forecast ($m), 2010–2017 68 Figure 48: Istodax Market Potential, Europe, Revenue Forecast ($m), 2012–2017 69 Figure 49: Istodax Market Potential, Japan, Revenue Forecast ($m), 2012–2017 70 Figure 50: Istodax (Romidepsin) – Drug Pipeline, by Phase, 2010 71 Figure 51: Istodax (Romidepsin) – Drug Pipeline, by Indication, 2010 72 Figure 52: Istodax (Romidepsin) – Drug Pipeline, by Phase and Indication, 2010 73 Figure 53: SWOT, Merck & Co, 2010 77 Figure 54: SWOT, Celgene Corporation, 2010 79 Figure 55: SWOT, Eisai, 2010 82 Figure 56: GBI Research Market Forecasting Model 87 | |
Companies mentioned
Merck & Co
Celgene Corporation
EISAI
To order this report:
Biotechnology Industry: Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma
Check our Company Profile, SWOT and Revenue Analysis!
| Contact: | |
| Nicolas Bombourg | |
| Reportlinker | |
| Email: nbo@reportlinker.com | |
| US: (805)652-2626 | |
| Intl: +1 805-652-2626 | |
SOURCE Reportlinker
Back to top
RELATED LINKS
http://www.reportlinker.com
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
PR Newswire Membership
Fill out a PR Newswire membership form or contact us at (888) 776-0942.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.
Featured Video
More in These Categories
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Free Investing Newsletter from Investor Uprising!
Learn to navigate the world's financial system and profit from leading companies.
Register for Investor Uprising, the people's investment site, for a free weekly newsletter, information, education and premium research including our latest IU Confidential Report - "All That Glitters: The Ultimate Gold Report".